Australian Capital Territory

Emergencies (Service Provider) Approval 2022 (No 4)

**Notifiable instrument NI2022–283**

made under the

Emergencies Act 2004, s 62 (Decision about approval)

**1 Name of instrument**

This instrument is the *Emergencies (Service Provider*) *Approval 2022 (No 4)*.

**2 Commencement**

This instrument commences on 02 June 2022.

**3 Approval**

I approve First Aid Australia Pty Ltd T/a Ambulance Service Australia (the provider) to provide ambulance services (the services) at events in the ACT.

**4 Condition of Approval**

Approval is subject to the conditions in Schedule 1.

**5 Expiry**

This instrument expires 01 June 2024.

Mick Gentleman MLA

Minister for Police and Emergency Services

19 May 2022

**SCHEDULE 1**

**CONDITIONS OF APPROVAL**

1. The provider must comply with all conditions set out in the Application for Approval to Provide Ambulance Services in the ACT – AF2015-140.
2. The provider must seek the consent of the Chief Officer, ACT Ambulance Service to provide the services at an event which was not specified in the application for approval, at least 7 days prior to the commencement of the event. The request must specify the dates and event precinct where the services are proposed to be provided, and any consent granted is subject on the services being delivered as specified in the request.
3. The provider must not transport any patient outside the event precinct notified to the Chief Officer, ACT Ambulance Service.
4. Only the personnel nominated in the provider’s application for approval under section 61 of the Emergencies Act 2004 are permitted to provide the services. Staff not nominated in the application for approval may only provide the services with the Chief Officer ACT Ambulance Service’s prior written approval.
5. The provider must provide the Chief Officer, ACT Ambulance Service copies of any updated or renewed insurance documentation if insurance is renewed during the approval period.
6. The provider must provide the Chief Officer, ACT Ambulance Service copies of any clinical or pharmaceutical management guidelines implemented or amended during the approval period.